IL22 and myeloid sarcoma: Hannes et al. conducted EAE experiments on wild-type mice, IL-22 deficient mice, IL-22BP deficient mice, and IL-22 and IL-22BP double deficient mice and concluded that the loss of control of IL-22 signal in IL-22BP deficient mice reduced the severity of EAE,which supported the protective effect of IL-22 in MS; thus, they suggested that IL-22BP could be used as a new target for MS (92).